1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow albinterferon alfa-2b: new trials by email Literature Review of albinterferon alfa-2b trials Research Report on albinterferon alfa-2b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects albinterferon alfa-2b, Pegasys® - Chronic Hepatitis B | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 141 | 2009-07-01 | 2011-01-06 |
| An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals Albinterferon, Ribavirin, Albuferon - HIV Infections, HCV | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 41 | 2007-06-18 | 2017-07-02 |
Bronchiolitis Obliterans Syndrome (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hepatitis C (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1)
China (1) · Hong Kong (1) · Poland (1) · Taiwan (1) · Thailand (1) · United States (1)